Immunovant (IMVT) Capital Expenditures (2019 - 2026)
Immunovant (IMVT) posted Capital Expenditures of -$69000.0 for Q1 2026, down 100.96% on a QoQ basis from $7.2 million in Q1 2025, and down 100.96% year-over-year from $7.2 million in Q1 2025.
Immunovant (IMVT) Capital Expenditures (2019 - 2026) Analysis & Trends
Immunovant's Capital Expenditures history runs 8 years deep, the most recent figure standing at -$69000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 100.96% year-over-year to -$69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69000.0 (down 100.89% YoY) and the FY2026 annual result came in at -$69000.0, down 100.89% from the prior year.
- Capital Expenditures was -$69000.0 for Q1 2026 at Immunovant, down from $7.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $7.9 million in Q3 2024 and bottomed at -$7.5 million in Q4 2024.
- A 5-year average of $641692.3 and a median of $45000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 245.16% — and 2024, when it soared 17631.11%.
- Immunovant's Capital Expenditures stood at $98000.0 in 2022, then slumped by 145.92% to -$45000.0 in 2023, then slumped by 16595.56% to -$7.5 million in 2024, then jumped by 195.54% to $7.2 million in 2025, then tumbled by 100.96% to -$69000.0 in 2026.
- Business Quant data shows IMVT's Capital Expenditures at -$69000.0 in Q1 2026, $7.2 million in Q1 2025, and -$7.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Immunovant | 7.18 Bn | 7.18 Bn | - | -69,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69,000.00 |
| Mar 31, 2026 | -69,000.00 |
| Mar 31, 2025 | 7.18 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | -7.51 Mn |
| Dec 31, 2024 | -7.51 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 182,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 98,000.00 |
| Dec 31, 2022 | 98,000.00 |